Targeted Intranasal Delivery of Antiretrovirals for NeuroAIDS: Opportunities, Barriers, and Formulation Strategies
DOI:
https://doi.org/10.31351/vol35iss3pp113-128Keywords:
Antiretroviral therapy , Intranasal delivery, Nanocarrier, NeuroAIDS, Nose-to-brain deliveryAbstract
NeuroAIDS refers to the spectrum of neuropsychiatric complications observed in approximately 30–50% of HIV/AIDS patients. Although the advent of antiretroviral therapy has reduced the severity of AIDS, mild cognitive deficits persist in nearly half of treated patients, highlighting limitations in central nervous system (CNS) drug delivery. These limitations are attributed to poor blood-brain barrier (BBB) permeability, P-glycoprotein efflux, low solubility, first-pass metabolism, and short half-lives of many ART drugs. Nose-to-brain drug delivery has emerged as a promising alternative, bypassing the BBB via olfactory and trigeminal pathways. This route offers direct CNS access while minimizing systemic exposure. Factors such as drug molecular weight, lipophilicity, pH, osmolality, viscosity, particle size, and surface charge significantly influence nasal drug absorption and brain targeting. Approaches to optimize nose-to-brain delivery include the use of prodrugs, permeation enhancers, mucoadhesive agents, enzyme inhibitors, and P-glycoprotein inhibitors. Despite encouraging preclinical data, challenges remain, including mucociliary clearance, enzymatic degradation, and species-specific anatomical variations that hinder translational research. A rational formulation design that considers physiological and physicochemical barriers is essential for clinical success. Nanocarriers—including nanovesicles, solid lipid nanoparticles (SLNs), and microemulsions—offer several advantages: they protect drugs from enzymatic degradation, improve solubility and stability, enable controlled release, and enhance mucoadhesion and uptake across the nasal mucosa. Overall, intranasal delivery systems, particularly those employing nanocarriers and functional excipients, offer a novel and efficient approach to managing NeuroAIDS by enhancing ART bioavailability in the CNS and improving drug access to HIV reservoirs in the brain.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Sarma A, Das MK. Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS. Mol Biomed. 2020;1(1):15. doi: 10.1186/s43556-020-00019-8
Wei J, Hou J, Su B, Jiang T, Guo C, Wang W, et al. The Prevalence of Frascati-Criteria-Based HIV-Associated Neurocognitive Disorder (HAND) in HIV-Infected Adults: A Systematic Review and Meta-Analysis. Front Neurol. 2020;11:581346. doi: 10.3389/fneur.2020.581346
Grant I, Franklin DR, Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 Jun 10;82(23):2055–62. doi: 10.1212/WNL.0000000000000492
Gill, A.J., Kolson, D.L. Chronic Inflammation and the Role for Cofactors (Hepatitis C, Drug Abuse, Antiretroviral Drug Toxicity, Aging) in HAND Persistence. Curr HIV/AIDS Rep 11, 325–335 (2014). https://doi.org/10.1007/s11904-014-0210-3
Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev. 2009 Jun;19(2):169–85.
Dheda M. Efavirenz and neuropsychiatric effects. South Afr J HIV Med. 2017;18(1):741. https://hdl.handle.net/10520/EJC-7358159c5
Ash MK, Al-Harthi L, Schneider JR. HIV in the Brain: Identifying Viral Reservoirs and Addressing the Challenges of an HIV Cure. Vaccines (Basel). 2021 Aug 5;9(8):867. https://doi.org/10.3390/vaccines9080867
Rani A, Ergün S, Karnati S, Jha HC. Understanding the link between neurotropic viruses, BBB permeability, and MS pathogenesis. J Neurovirol. 2024 Feb;30(1):22–38. doi: 10.1007/s13365-023-01190-8
Michalicová A, Bhide K, Bhide M, Kováč A. How viruses infiltrate the central nervous system. Acta Virol. 2017;61(4):393-400. doi: 10.4149/av_2017_401
Subra C, Trautmann L. Role of T Lymphocytes in HIV Neuropathogenesis. Curr HIV/AIDS Rep. 2019 Jun;16(3):236–43. doi: 10.1007/s11904-019-00445-6
Iacob SA, Iacob DG, Jugulete G. Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment-Clinical Points of View and Practical Considerations. Front Pharmacol. 2017;8:831. doi: 10.3389/fphar.2017.00831
Blassel L, Zhukova A, Villabona-Arenas CJ, Atkins KE, Hué S, Gascuel O. Drug resistance mutations in HIV: new bioinformatics approaches and challenges. Curr Opin Virol. 2021 Dec;51:56-64. doi: 10.1016/j.coviro.2021.09.009
Nicol MR, McRae M. Treating viruses in the brain: Perspectives from NeuroAIDS. Neurosci Lett. 2021 Mar 23;748:135691. doi: 10.1016/j.neulet.2021.135691
Kumar S, Maurya V, Dandu H, Bhatt M, Saxena S. Global perspective of novel therapeutic strategies for the management of NeuroAIDS: novel drug delivery methods for NeuroAIDS. Biomol Concepts. 2018;9(1):33-42. https://doi.org/10.1515/bmc-2018-0005
Schenfeld EM, Ribone SR, Quevedo MA. Stability and plasmatic protein binding of novel zidovudine prodrugs: Targeting site ii of human serum albumin. Eur J Pharm Sci. 2018 Mar 30;115:109-118. doi: 10.1016/j.ejps.2018.01.024
Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses. 2003 Sep;19(9):825-35. doi: 10.1089/088922203769232629
Illamola SM, Hirt D, Tréluyer JM, Urien S, Benaboud S. Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines. Drug Discov Today. 2015 Apr;20(4):466-74. doi: 10.1016/j.drudis.2014.11.010
Butar-Butar ME, Wathoni N, Ratih H, Wardhana YW. Solid dispersion technology for improving the solubility of antiviral drugs. Pharm Sci Res. 2023;10(1):3.doi: 10.7454/psr.v10i1.1292
Khan SA, Rehman S, Nabi B, Iqubal A, Nehal N, Fahmy UA, Kotta S, Baboota S, Md S, Ali J. Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS. Pharmaceutics. 2020 Nov 6;12(11):1059. doi: 10.3390/pharmaceutics12111059.
Belgamwar AV, Khan SA, Yeole PG. Intranasal dolutegravir sodium loaded nanoparticles of hydroxypropyl-beta-cyclodextrin for brain delivery in Neuro-AIDS. J Drug Deliv Sci Technol. 2019 Aug 1;52:1008–20.https://doi.org/10.1016/j.jddst.2019.06.014.
Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res. 2022 Apr;12(4):735–57. doi: 10.1007/s13346-020-00891-5
Wu X, Zang R, Qiu Y, Zhang Y, Peng J, Cheng Z, et al. Intranasal Drug Delivery Technology in the Treatment of Central Nervous System Diseases: Challenges, Advances, and Future Research Directions. Pharmaceutics. 2025 Jun 13;17(6):775. doi: 10.3390/pharmaceutics17060775
Huang Q, Chen Y, Zhang W, Xia X, Li H, Qin M, Gao H. Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases. J Control Release. 2024 Feb;366:519-534.https://doi.org/10.1016/j.jconrel.2023.12.054
Purvin S, Vuddanda PR, Singh SK, Jain A, Singh S. Pharmacokinetic and tissue distribution study of solid lipid nanoparticles of zidovudine in rats. J Nanotechnol. 2014;2014:1–7. http://dx.doi.org/10.1155/2014/854018
Furubayashi T, Inoue D, Kimura S, Tanaka A, Sakane T. Evaluation of the pharmacokinetics of intranasal drug delivery for targeting cervical lymph nodes in rats. Pharmaceutics. 2021;13(9):1363. doi:10.3390/pharmaceutics13091363
Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004 Jan;127(2):481–96. doi: 10.1016/j.neuroscience.2004.05.029
Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH. Mechanism of intranasal drug delivery directly to the brain. Life Sciences. 2018 Feb;195:44–52. DOI: 10.1016/j.lfs.2017.12.025
Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc LJ, Le Guen M, Fischler M, Devillier P. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012 Jun;134(3):366-79. doi: 10.1016/j.pharmthera.2012.03.003
Agu RU. Challenges in Nasal Drug absorption: How Far have We come? Ther Deliv. 2016 Jul;7(7):495–510. doi: 10.4155/tde-2016-0022
Sarkar MA. Drug metabolism in the nasal mucosa. Pharm Res. 1992 Jan;9(1):1–9. doi: 10.1023/a:1018911206646
Kandimalla KK, Donovan MD. Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae. Pharm Res. 2005 Jul;22(7):1121-8. https://doi.org/10.1007/s11095-005-5420-3
Bors LA, Bajza Á, Mándoki M, Tasi BJ, Cserey G, Imre T, Szabó P, Erdő F. Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats. Brain Res Bull. 2020 Jul;160:65-73. https://doi.org/10.1016/j.brainresbull.2020.04.012
Huang Q, Chen X, Yu S, Gong G, Shu H. Research progress in brain-targeted nasal drug delivery. Front Aging Neurosci. 2024 Jan 17;15:1341295. doi: 10.3389/fnagi.2023.1341295
Saitani, E.-M.; Pippa, N.; Perinelli, D.R.; Forys, A.; Papakyriakopoulou, P.; Lagopati, N.; Bonacucina, G.; Trzebicka, B.; Gazouli, M.; Pispas, S.; et al. Fabricating Polymer/Surfactant/Cyclodextrin Hybrid Particles for Possible Nose-to-Brain Delivery of Ropinirole Hydrochloride: In Vitro and Ex Vivo Evaluation. Int. J. Mol. Sci. 2024, 25, 1162. https://doi.org/10.3390/ijms25021162
Saba Abdulhadi Jaber, Nawal Ayash Rajab. Preparation and In vitro/Ex vivo Evaluation of Nanoemulsion-Based in Situ Gel for Intranasal Delivery of Lasmiditan. IJPS. 2024 Sep 15;33(3):128–41. https://doi.org/10.31351/vol33iss3pp128-141
Tamer MA, Kassab HJ. Optimizing Intranasal Amisulpride Loaded Nanostructured Lipid Carriers: Formulation, Development, and Characterization Parameters. PNT. 2025 Apr;13(2):287–302. https://doi.org/10.2174/0122117385301604240226111533
Illum L. Nasal drug delivery--possibilities, problems and solutions. J Control Release. 2003 Feb 21;87(1–3):187–98. doi: 10.1016/s0168-3659(02)00363-2
Raghav M, Gupta V, Awasthi R, Singh A, Kulkarni GT. Nose-to-brain drug delivery: challenges and progress towards brain targeting in the treatment of neurological disorders. J Drug Deliv Sci Technol. 2023 Sep;86:104756.https://doi.org/10.1016/j.jddst.2023.104756
Papakyriakopoulou P, Valsami G. The nasal route for nose-to-brain drug delivery: advanced nasal formulations for CNS disorders. Expert Opin Drug Deliv. 2025 Jun;22(6):823-839. doi: 10.1080/17425247.2025.2489553
Salade L, Wauthoz N, Goole J, Amighi K. How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods. Int J Pharm. 2019 Apr;561:47–65. doi: 10.1016/j.ijpharm.2019.02.026
Scherließ R. Nasal formulations for drug administration and characterization of nasal preparations in drug delivery. Ther Deliv. 2020 Mar;11(3):183-191. doi: 10.4155/tde-2019-0086
Koo J, Lim C, Oh KT. Recent Advances in Intranasal Administration for Brain-Targeting Delivery: A Comprehensive Review of Lipid-Based Nanoparticles and Stimuli-Responsive Gel Formulations. Int J Nanomedicine. 2024 Feb 23;19:1767-1807. doi: 10.2147/IJN.S439181
Ugwoke MI, Agu RU, Jorissen M, Augustijns P, Sciot R, Verbeke N, Kinget R. Toxicological investigations of the effects carboxymethylcellulose on ciliary beat frequency of human nasal epithelial cells in primary suspension culture and in vivo on rabbit nasal mucosa. Int J Pharm. 2000 Sep 15;205(1-2):43-51. doi: 10.1016/s0378-5173(00)00484-1
Wei S, Zhai Z, Kong X, Wu C, Zhu B, Zhao Z, Zhang X. The review of nasal drug delivery system: The strategies to enhance the efficiency of intranasal drug delivery by improving drug absorption. Int J Pharm. 2025 May 15;676:125584. https://doi.org/10.1016/j.ijpharm.2025.125584
Alkufi HK, Kassab HJ. Nanospanlastic in situ Gel for Nose to Brain Delivery of Nimodipine: In vitro Optimization and in vivo Pharmacokinetic Study. Al-Rafidain J Med Sci. 2025 Feb 18;8(1):97–105. doi: https://doi.org/10.54133/ajms.v8i1.1687
Taher SS, Kadhem Al-Kinani K. In vivo Brain Pharmacokinetics of Dolutegravir Sodium-Loaded Nanostructured Lipid Carrier in situ Gel: Comparative Study with an Intravenous Drug Solution. Al-Rafidain J Med Sci. 2025 Feb 22;8(1):115–25. https://doi.org/10.54133/ajms.v8i1.1692
Mistry A, Stolnik S, Illum L. Nose-to-Brain Delivery: Investigation of the Transport of Nanoparticles with Different Surface Characteristics and Sizes in Excised Porcine Olfactory Epithelium. Mol Pharm. 2015 Aug 3;12(8):2755-66. doi: 10.1021/acs.molpharmaceut.5b00088
Ahmad E, Feng Y, Qi J, Fan W, Ma Y, He H, Xia F, Dong X, Zhao W, Lu Y, Wu W. Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles. Nanoscale. 2017 Jan 19;9(3):1174-1183. doi: 10.1039/c6nr07581a
Chen Y, Zhang C, Huang Y, Ma Y, Song Q, Chen H, Jiang G, Gao X. Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway. Adv Drug Deliv Rev. 2024 Apr;207:115196. doi: 10.1016/j.addr.2024.115196
Quiñones JP, Peniche H, Peniche C. Chitosan Based Self-Assembled Nanoparticles in Drug Delivery. Polymers. 2018 Feb 26;10(3):235. https://doi.org/10.3390/polym10030235
Bonaccorso A, Musumeci T, Serapide MF, Pellitteri R, Uchegbu IF, Puglisi G. Nose to brain delivery in rats: Effect of surface charge of rhodamine B labeled nanocarriers on brain subregion localization. Colloids Surf B Biointerfaces. 2017 Jun 1;154:297-306. doi: 10.1016/j.colsurfb.2017.03.035
Kurano T, Kanazawa T, Ooba A, Masuyama Y, Maruhana N, Yamada M, Iioka S, Ibaraki H, Kosuge Y, Kondo H, Suzuki T. Nose-to-brain/spinal cord delivery kinetics of liposomes with different surface properties. J Control Release. 2022 Apr;344:225-234. doi: 10.1016/j.jconrel.2022.03.017
Qiu Y, Huang S, Peng L, Yang L, Zhang G, Liu T, Yan F, Peng X. The Nasal-Brain Drug Delivery Route: Mechanisms and Applications to Central Nervous System Diseases. MedComm (2020). 2025 Jun 6;6(6):e70213.doi: 10.1002/mco2.70213
Mickenhagen A, Siefer O, Neugebauer P, Stennert E. Der Einfluss verschiedener alpha-Sympathomimetika und Benzalkoniumchlorid auf die Zilienschlagfrequenz humaner Flimmerzellen in vitro (The influence of different alpha-sympathomimetic drugs and benzalkoniumchlorid on the ciliary beat frequency of in vitro cultured human nasal mucosa cells). Laryngorhinootologie. 2008 Jan;87(1):30-8. German. doi: 10.1055/s-2007-966891
Gorelik E. Cytotoxic effects of lectins. Methods Mol Med. 1998;9:453–9. doi: 10.1385/0-89603-396-1:453
Chamanza R, Wright JA. A Review of the Comparative Anatomy, Histology, Physiology and Pathology of the Nasal Cavity of Rats, Mice, Dogs and Non-human Primates. Relevance to Inhalation Toxicology and Human Health Risk Assessment. J Comp Pathol. 2015 Nov;153(4):287-314.doi: 10.1016/j.jcpa.2015.08.009
Al-Tamimi D, Al-Kinani K, Taher S, Hussein A. Effect of food on the pharmacokinetics of fluoxetine in healthy male adult volunteers. Iraqi J Pharm Sci (Internet). 2023 Feb 18 (cited 2025 Aug 11);31(Suppl):153-61. Available from: https://bijps.uobaghdad.edu.iq/index.php/bijps/article/view/1927
Jeong SH, Jang JH, Lee YB. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Investig. 2023;53(1):119-152. doi: 10.1007/s40005-022-00589-5
Dalpiaz A, Fogagnolo M, Ferraro L, Capuzzo A, Pavan B, Rassu G, Salis A, Giunchedi P, Gavini E. Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries. Antiviral Res. 2015 Nov;123:146-57.doi: 10.1016/j.antiviral.2015.09.013
Ghadiri M, Young PM, Traini D. Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes. Pharmaceutics. 2019 Mar 11;11(3):113. . DOI: 10.3390/pharmaceutics11030113
Fukakusa S, Suzuki C, Sasaki K, Sonoda Y, Hatano Y, Haruta S, Magata Y. Brain drug delivery from the nasal olfactory region is enhanced using lauroylcholine chloride: An estimation using in vivo PET imaging. Nucl Med Biol. 2024 Nov-Dec;138-139:108968.doi: 10.1016/j.nucmedbio.2024.108968
Hamzah ML, Kassab HJ. Formulation and Characterization of Intranasal Drug Delivery of Frovatriptan-Loaded Binary Ethosomes Gel for Brain Targeting. Nanotechnol Sci Appl. 2024 Jan 16;17:1-19. doi: 10.2147/NSA.S442951
Taher SS, Al-Kinani KK. Formulation and characterization of dolutegravir sodium-loaded nanostructured lipid carrier in situ gel for targeted brain delivery via intranasal route. OpenNano. 2025;100270. doi:10.1016/j.onano.2025.100270.
Alabdly A, J. Kassab H. Formulation Variables Effect on Gelation Temperature of Nefopam Hydrochloride intranasal in Situ Gel (Conference Paper) #. IJPS. 2023 Feb 16;31(Suppl.):32–44. https://doi.org/10.31351/vol31issSuppl.pp32-44
Alkufi HK, Kassab HJ. Formulation and Evaluation of Sustained Release Sumatriptan Mucoadhesive Intranasal in-Situ Gel. IJPS. 2019 Dec 22;28(2):95–104. https://doi.org/10.31351/vol28iss2pp95-104
Jintapattanakit A, Peungvicha P, Sailasuta A, Kissel T, Junyaprasert VB. Nasal absorption and local tissue reaction of insulin nanocomplexes of trimethyl chitosan derivatives in rats. J Pharm Pharmacol. 2010 May;62(5):583–91. doi: 10.1211/jpp.62.05.0004
Kim YS, Sung DK, Kim H, Kong WH, Kim YE, Hahn SK. Nose-to-brain delivery of hyaluronate - FG loop peptide conjugate for non-invasive hypoxic-ischemic encephalopathy therapy. J Control Release. 2019 Aug 10;307:76-89. doi: 10.1016/j.jconrel.2019.06.021
öscher W, Gericke B. Novel Intrinsic Mechanisms of Active Drug Extrusion at the Blood-Brain Barrier: Potential Targets for Enhancing Drug Delivery to the Brain? Pharmaceutics. 2020 Oct 14;12(10):966. DOI: 10.3390/pharmaceutics12100966
Gomes MJ, Kennedy PJ, Martins S, Sarmento B. Delivery of siRNA silencing P-gp in peptide-functionalized nanoparticles causes efflux modulation at the blood-brain barrier. Nanomedicine (Lond). 2017 Jun;12(12):1385-1399. doi: 10.2217/nnm-2017-0023
Emad NA, Ahmed B, Alhalmi A, Alzobaidi N, Al-Kubati SS. Recent progress in nanocarriers for direct nose to brain drug delivery. J Drug Deliv Sci Technol. 2021 Aug;64:102642. https://doi.org/10.1016/j.jddst.2021.102642
Taher SS, Al-Kinani KK. Current nanotechnological strategies for delivery of anti-retroviral drugs: overview and future prospects. Curr Drug Ther. 2024 Oct 29;20. Available from:https://www.eurekaselect.com/235841/article.doi: 10.2174/0115748855331460241017100207
Alwan ZS, Rajab NA. Preparation and characterization of febuxostat as nanosuspension. Iraqi J Pharm Sci. 2025 Feb 15;33(4 Suppl 1):261–270. https://doi.org/10.31351/vol33iss(4SI)pp261-270
Ramadhan SH, Al-Kinani KK. Statistical Optimization and Characterization of Nimodipine Transferosomes. Al-Rafidain J Med Sci. 2024 Sep 14;7(1(Special)):S77-83. https://doi.org/10.54133/ajms.v7i1(Special).1015
Salman A. H., Alkufi H. K., Taher S. S., Al-mahmood S., Haiss M. A.: Response surface optimization and in vitro study of nasal solusomes nanovesicles for the bioavailability improvement and brain targetting of sumatriptan. Ep. Klin. Farmakol. kai Farmakokinet. 2024;42(Suppl 1):107–117. DOI: 10.61873/RNYL6796
Saka R, Chella N, Khan W. Development of Imatinib Mesylate-Loaded Liposomes for Nose to Brain Delivery: In Vitro and In Vivo Evaluation. AAPS PharmSciTech. 2021 Jun 28;22(5):192. doi: 10.1208/s12249-021-02072-0
Samudre S, Tekade A, Thorve K, Jamodkar A, Parashar G, Chaudhari N. Xanthan Gum Coated Mucoadhesive Liposomes for Efficient Nose to Brain Delivery of Curcumin. DDL. 2016 Apr 1;5(3):201–7. doi: 10.2174/2210303106666160120215857
Eid HM, Elkomy MH, El Menshawe SF, Salem HF. Transfersomal nanovesicles for nose-to-brain delivery of ofloxacin for better management of bacterial meningitis: formulation, optimization by Box-Behnken design, characterization and in vivo pharmacokinetic study. J Drug Deliv Sci Technol. 2019 Dec;54:101304.https://doi.org/10.1016/j.jddst.2019.101304
Shelke S, Shahi S, Jadhav K, Dhamecha D, Tiwari R, Patil H. Thermoreversible nanoethosomal gel for the intranasal delivery of Eletriptan hydrobromide. J Mater Sci: Mater Med. 2016 Jun;27(6):103. doi: 10.1007/s10856-016-5713-6
Patel RJ, Parikh RH. Intranasal delivery of topiramate nanoemulsion: Pharmacodynamic, pharmacokinetic and brain uptake studies. Int J Pharm. 2020 Jul 30;585:119486. doi: 10.1016/j.ijpharm.2020.119486
Kondapuram P, Sahoo SK. A review of merely polymeric nanoparticles in recent drug delivery system. Asian J Pharm Clin Res. 2022 Apr;15(4):4-12. doi:10.22159/ajpcr.2022.v15i4.43239.
Nair AB, Chaudhary S, Jacob S, Patel D, Shinu P, Shah H, Chaudhary A, Aldhubiab B, Almuqbil RM, Alnaim AS, Alqattan F, Shah J. Intranasal Administration of Dolutegravir-Loaded Nanoemulsion-Based In Situ Gel for Enhanced Bioavailability and Direct Brain Targeting. Gels. 2023 Feb 3;9(2):130. doi: 10.3390/gels9020130
Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, Yang CH. Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB. Pharmaceutics. 2021 Jul 31;13(8):1183. doi: 10.3390/pharmaceutics13081183
Raj R, Kolay A, Havelikar U. A review on solid lipid nanoparticles. Int J Curr Pharm Res. 2023 Sep;15(5):10-16. doi:10.22159/ijcpr.2023v15i5.3051.
Yasir M, Chauhan I, Zafar A, Verma M, Alruwaili NK, Noorulla KM, et al. Glyceryl behenate-based solid lipid nanoparticles as a carrier of haloperidol for nose to brain delivery: formulation development, in-vitro, and in-vivo evaluation. Braz J Pharm Sci. 2022;58:e20254. http://dx.doi.org/10.1590/s2175-97902022e20254
Bazargani A, Hejazi M, Fernandez M, Cordeiro A, Tsala Ebode J, Lewinski N, da Rocha S, Golshahi L. PEGylated solid lipid nanoparticles for the intranasal delivery of combination antiretroviral therapy composed of Atazanavir and Elvitegravir to treat NeuroAIDS. Int J Pharm. 2025 Feb 10;670:125166. doi: 10.1016/j.ijpharm.2025.125166
Downloads
Published
License
Copyright (c) 2026 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
